Trial · NCT07895901
Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
NCT07895901, Recruiting, University Hospital, Strasbourg, France
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry. Trials, record NCT07895901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895901
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
- NCT number
- NCT07895901
- Status
- Recruiting
- Enrollment
- 50 participants, estimated
- Lead sponsor
- University Hospital, Strasbourg, France
- Conditions
- Acute Myeloid Leukemia, Myeloid Hematological Malignancies, Normal Hematopoietic Stem and Progenitor Cells
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CD180 Expression in Normal and Pathological CD34+ Cells | During the 6-month data collection period, from January 21, 2026, to July 21, 2027. | Percentage of CD34+ cells expressing CD180 above the levels observed in negative control populations (T lymphocytes and neutrophils), and intensity of CD180 expression measured by antibody-based fluorescence intensity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895901
GET https://conductscience.org/api/trials/v1/NCT07895901/registered